<DOC>
	<DOCNO>NCT00450736</DOCNO>
	<brief_summary>RATIONALE : Celecoxib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Radiation therapy use high-energy x-ray kill tumor cell . Giving celecoxib together radiation therapy surgery may kill tumor cell remain surgery . PURPOSE : This phase I trial study side effect best dose celecoxib give together radiation therapy treat patient stage II stage III soft tissue sarcoma arm , hand , leg , foot remove surgery .</brief_summary>
	<brief_title>Celecoxib Radiation Therapy Treating Patients With Stage II Stage III Soft Tissue Sarcoma Arm , Hand , Leg , Foot That Has Been Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose adjuvant celecoxib administer radiotherapy patient resect stage II III soft tissue sarcoma extremity . OUTLINE : This dose-escalation study celecoxib . Beginning within 10 week recent resection , patient undergo standard radiotherapy daily , 5 day week , week 1-7 . Patients also receive oral celecoxib twice daily week 1-7 absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos celecoxib maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 6 patient experience dose-limiting toxicity . A maximum 6 patient treated MTD . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 24 patient accrue study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Histiocytoma</mesh_term>
	<mesh_term>Histiocytoma , Benign Fibrous</mesh_term>
	<mesh_term>Histiocytoma , Malignant Fibrous</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm soft tissue sarcoma extremity , include follow disease type : Liposarcoma Leiomyosarcoma Synovial cell sarcoma Malignant fibrous histiocytoma Spindle cell sarcoma Fibrosarcoma Chondrosarcoma Angiosarcoma Hemangiopericytoma Neurofibrosarcoma The following disease type exclude : Kaposi 's sarcoma Rhabdomyosarcoma Dermatofibrosarcoma Epithelioid cell sarcoma Ewing 's sarcoma Osteosarcoma Intermediate highgrade tumor ≥ 5.0 cm 1 dimension ( stage II III disease ) Locally resect disease One prior wide local excision sarcoma location extremity within past 6 month allow Prior neoadjuvant chemotherapy ( ≤ 3 course ) , follow limbsparing surgical resection sarcoma find &lt; 90 % pathological tumor necrosis allow Prior resection extremity mass subsequently find sarcoma meeting study criterion , follow ≤ 3 course chemotherapy ( independent percentage pathological tumor necrosis ) allow No evidence nodal distant metastasis PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % WBC ≥ 3,000/mm³ Absolute granulocyte count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Bilirubin ≤ 1.5 mg/dL SGPT SGOT ≤ 2.5 time upper limit normal ( ULN ) Creatinine ≤ 1.5 time ULN Calcium ≤ 1.3 time ULN No prior malignancy except cutaneous nonmelanomatous skin cancer , carcinoma situ cervix , cancer patient diseasefree least 5 year No history allergic reaction sulfonamide NSAIDs No known hypersensitivity celecoxib component formulation No known HIV positivity No known coronary artery disease No cardiac event kind within past 6 month No concurrent unstable cardiac status Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior radiotherapy extremity require radiation study No prior systemic chemotherapy malignant tumor No concurrent dilantin lithium carbonate No concurrent prescription overthecounter nonsteroidal antiinflammatory agent ( NSAIDs )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>chondrosarcoma</keyword>
	<keyword>adult angiosarcoma</keyword>
	<keyword>adult fibrosarcoma</keyword>
	<keyword>adult leiomyosarcoma</keyword>
	<keyword>adult liposarcoma</keyword>
	<keyword>adult neurofibrosarcoma</keyword>
	<keyword>adult synovial sarcoma</keyword>
	<keyword>childhood angiosarcoma</keyword>
	<keyword>childhood fibrosarcoma</keyword>
	<keyword>childhood leiomyosarcoma</keyword>
	<keyword>childhood liposarcoma</keyword>
	<keyword>childhood neurofibrosarcoma</keyword>
	<keyword>childhood synovial sarcoma</keyword>
	<keyword>nonmetastatic childhood soft tissue sarcoma</keyword>
	<keyword>stage II adult soft tissue sarcoma</keyword>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>adult malignant fibrous histiocytoma</keyword>
	<keyword>adult malignant hemangiopericytoma</keyword>
	<keyword>childhood malignant hemangiopericytoma</keyword>
	<keyword>localize childhood malignant fibrous histiocytoma bone</keyword>
</DOC>